Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kiira Mäklin

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
BMC Health Services Research|April 4, 2023
Diagnostic groups of hospital stays and outpatient visits during 10 years before Alzheimer's diseaseKiira Mäklin, Pasi Lampela, Julian Lin, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|April 11, 2020
Evaluation of FASN inhibitors by a versatile toolkit reveals differences in pharmacology between human and rodent FASN preparations and in antiproliferative efficacy in vitro vs. in situ in human cancer cellsProsanta K Singha, Kiira Mäklin, Taina Vihavainen, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 11, 2024
Coronary Artery Disease Risk Variant Dampens the Expression of CALCRL by Reducing HSF Binding to Shear Stress Responsive Enhancer in Endothelial Cells In VitroIlakya Selvarajan, Miika Kiema, Ru-Ting Huang, et al.
Neurology|August 14, 2024
Risk Variants Associated With Normal Pressure Hydrocephalus: Genome-Wide Association Study in the FinnGen CohortJoel Räsänen, Sami Heikkinen, Kiira Mäklin, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
BMC Health Services Research|April 4, 2023
Diagnostic groups of hospital stays and outpatient visits during 10 years before Alzheimer's diseaseKiira Mäklin, Pasi Lampela, Julian Lin, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|April 11, 2020
Evaluation of FASN inhibitors by a versatile toolkit reveals differences in pharmacology between human and rodent FASN preparations and in antiproliferative efficacy in vitro vs. in situ in human cancer cellsProsanta K Singha, Kiira Mäklin, Taina Vihavainen, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|April 11, 2024
Coronary Artery Disease Risk Variant Dampens the Expression of CALCRL by Reducing HSF Binding to Shear Stress Responsive Enhancer in Endothelial Cells In VitroIlakya Selvarajan, Miika Kiema, Ru-Ting Huang, et al.
Neurology|August 14, 2024
Risk Variants Associated With Normal Pressure Hydrocephalus: Genome-Wide Association Study in the FinnGen CohortJoel Räsänen, Sami Heikkinen, Kiira Mäklin, et al.
Pageof 1